Subscribe to RSS
Primary Cervical Carcinosarcoma: Report of a Rare CaseFunding None.
Background Carcinosarcomas are malignant mixed Müllerian tumors (MMMT), containing both epithelial and mesenchymal components. Carcinosarcomas of the uterine cervix comprise an extremely rare histopathological entity, with less than 150 cases reported in the literature to date.
Materials and Methods A 79-year-old postmenopausal female patient was referred to our gynecological department due to a pelvic mass and vaginal bleeding. A cervical curettage was performed and the histological report revealed a malignant neoplasm with high cellularity consisting of two components; the first was a chondrosarcoma and the latter a adenocarcinoma. A diagnosis of MMMT was confirmed through immunohistochemical (IHC) staining. Neoadjuvant chemotherapy and radiotherapy were implemented, and a year later the patient underwent a radical hysterectomy and oncological pelvic lymph node dissection. She remains disease-free 12 months postoperatively.
Conclusion Primary cervical carcinosarcomas are extremely rare tumors demonstrating a bipartite profile. Preoperative diagnosis with appropriate immunochemistry testing of this rare entity is crucial to decision making.
G.T., A.K., Z.F., A.A.S., T.N., A.D., and E.N.K. contributed to conception and design. A.K., E.N.K., and A.S. were responsible for overall supervision. A.K., M.K., A.A.S., and G.T. drafted the manuscript, which was revised by E.N.K. All authors read and approved the final manuscript.
Received: 26 December 2021
Accepted: 31 January 2022
Article published online:
02 August 2022
© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
- 1 Arend R, Doneza JA, Wright JD. Uterine carcinosarcoma. Curr Opin Oncol 2011; 23 (05) 531-536
- 2 Mbatani N, Olawaiye AB, Prat J. Uterine sarcomas. Int J Gynaecol Obstet 2018; 143 (suppl 2): 51-58
- 3 Kanthan R, Senger JL. Uterine carcinosarcomas (malignant mixed Müllerian tumours): a review with special emphasis on the controversies in management. Obstet Gynecol Int 2011; 2011: 470795
- 4 Wells M, Oliva E, Palacios J, Prat J. Mixed epithelial and mesenchymal tumors. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, eds. WHO Classification of Tumours of Female Reproductive Organs. Lyon: International Agency for Research on Cancer; 2014: 151-152
- 5 Grayson W, Taylor LF, Cooper K. Carcinosarcoma of the uterine cervix: a report of eight cases with immunohistochemical analysis and evaluation of human papillomavirus status. Am J Surg Pathol 2001; 25 (03) 338-347
- 6 de Jong RA, Nijman HW, Wijbrandi TF, Reyners AK, Boezen HM, Hollema H. Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component. Mod Pathol 2011; 24 (10) 1368-1379
- 7 Singh R. Review literature on uterine carcinosarcoma. J Cancer Res Ther 2014; 10 (03) 461-468
- 8 Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky P, Finkelstein SD. Carcinosarcomas (malignant mixed Mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998; 29 (01) 82-87
- 9 Cherniack AD, Shen H, Walter V. et al; Cancer Genome Atlas Research Network. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell 2017; 31 (03) 411-423
- 10 Varela-Duran J, Nochomovitz LE, Prem KA, Dehner LP. Postirradiation mixed Müllerian tumors of the uterus: a comparative clinicopathologic study. Cancer 1980; 45 (07) 1625-1631
- 11 Kimyon Comert G, Turkmen O, Karalok A, Basaran D, Bulbul D, Turan T. Therapy modalities, prognostic factors, and outcome of the primary cervical carcinosarcoma: meta-analysis of extremely rare tumor of cervix. Int J Gynecol Cancer 2017; 27 (09) 1957-1969
- 12 Homesley HD, Filiaci V, Markman M. et al; Gynecologic Oncology Group. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25 (05) 526-531
- 13 Galaal K, van der Heijden E, Godfrey K. et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2013; 2013 (02) CD006812
- 14 Vordermark D, Medenwald D, Izaguirre V, Sieker F, Marnitz S. The role of postoperative radiotherapy for carcinosarcoma of the uterus. Cancers (Basel) 2020; 12 (12) 3573
- 15 Wilkinson-Ryan I, Frolova AI, Liu J. et al. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma. Int J Gynecol Cancer 2015; 25 (01) 63-68
- 16 Kehoe S, Hook J, Nankivell M. et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386 (9990): 249-257
- 17 Matsuo K, Johnson MS, Im DD. et al. Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. J Surg Oncol 2018; 117 (03) 488-496
- 18 Wolfson AH, Wolfson DJ, Sittler SY. et al. A multivariate analysis of clinicopathologic factors for predicting outcome in uterine sarcomas. Gynecol Oncol 1994; 52 (01) 56-62
- 19 Amant F, Cadron I, Fuso L. et al. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 2005; 98 (02) 274-280